ImmunoPrecise Antibodies has developed the LENSai?s integrated intelligence platform powered by HYFT technology. This patented solution offers unprecedented data integration and fusion capabilities, allowing for seamless integration through one AI framework. IPA reports that companies like META are trying to develop similar solutions on their own.

However, LENSai's current capability enables the creation of actionable data, providing a deep understanding of the specif ic context and connections in biology. By leveraging this technology, valuable predictions can be made, and new information and insights can be uncovered. ImmunoPrecise Antibodies is a leading Contract Research Organization (CRO) in the biopharmaceutical industry, recognized for its expertise and track record.

With over a decade of experience, IPA offers a diverse range of specialized services - including antibody discovery and development - utilizing various cutting-edge techniques and models. The company boasts a significant portfolio of successful projects, having completed 135 memory B cell programs since 2019. This extensive range of programs demonstrates IPA's commitment to delivering high-quality therapeutic antibodies to clients.

LENSai is the company's latest contribution to the biotech field. The unique feature of LENSai is its ability to connect the fundamental pillars of the biosphere into one comprehensive framework. These pillars consist of sequence, structure and function of a molecule.

LENSai, powered by the company's patented HYFT technology, seamlessly integrates vast amounts of multi-omics data, enabling more complex analyses in the field of life science discovery. In a single framework, it handles various types of biological data, including DNA, RNA, protein sequences and structural information generated by methods such as Alpha Fold, ESM-2, Rosetta Fold, Cryo-EM, and Crystallography. Additionally, LENSai incorporates information from peer-reviewed literature, patents and clinical trials, offering a comprehensive approach to biological research and innovation.

HYFT technology - developed and patented by IPA's subsidiary Biostrand - offers a key advantage in that it optimizes potential therapeutic drug candidates at an early stage using the multi-functional LENSai in silico humanization platform integrated with its patented HYFT technology. This allows a multitude of potential therapies to be analyzed concurrently, which in turn reduces analysis time and costs and helps ensure that only the most promising candidates proceed further into the drug discovery process. Incorporated into the LENSai technology, the HYFT technology screens the entire human proteome (the entire complement of proteins that is or can be expressed by a cell, tissue or organism), as well as various animal proteomes, against candidate therapeutics.

The company reports that this screening is accomplished in underone minute per candidate molecule. The process advances the most 'human-like' molecules - speeding up humanization, reducing the manipulation required before use in clinical trials and offering a rapid, scalable, and cost-effective alternative to transgenic animal models.